학술논문
Quartic CAR-T Cell Bridging to Twice Allo-HSCT Therapy in a Patient with Acute Lymphoblastic Leukemia.
Document Type
Article
Author
Source
Subject
*LYMPHOBLASTIC leukemia
*CANCER chemotherapy
*CELL receptors
*RETROSPECTIVE studies
*TREATMENT effectiveness
*ANEMIA
*PATHOLOGIC complete response
*HEMATOLOGIC malignancies
*LYMPHOCYTIC leukemia
*RESEARCH funding
*HEMATOPOIETIC stem cell transplantation
*THROMBOCYTOPENIA
*LEUCOCYTE disorders
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
1660-3796
Abstract
Introduction: Chimeric antigen receptor T (CAR-T) cell therapy is an effective bridging treatment for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in relapsed or refractory acute lymphoblastic leukemia (ALL). However, repetitive CAR-T cell therapy and allo-HSCT can only be performed in a few patients because of technical difficulties and patients' physical, economic, and social conditions. Case Presentation: A 23-year-old female patient with second relapsed B-cell ALL (B-ALL) underwent human-murine chimeric CD19 CAR-T cell therapy twice, human-murine chimeric CD22 CAR-T cell therapy once, and humanized CD19 CAR-T cell therapy once. Moreover, she was sequentially bridged to her mother donor allo-HSCT once and cousin donor allo-HSCT once. Conclusion: Repetitive CAR-T cell therapy bridging to repetitive allo-HSCT is still a safe and active therapeutic strategy for patients with relapsed or refractory ALL. [ABSTRACT FROM AUTHOR]